Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 11/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | EED | O75530 | 1/20 | 0.32 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.32 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.32 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14716892 | 0.81 | KDM4E (0.38) | KDM4EALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL16344617 | 0.79 | EZH2 (0.40) | KDM4EALDH1A1LMNAEZH2HSD17B10 | |
| SCHEMBL16344535 | 0.77 | KDM4E (0.39) | KDM4EALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL9280162 | 0.76 | ALDH1A1 (0.36) | KDM4EALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL14727106 | 0.75 | KDM4E (0.41) | KDM4EALDH1A1EZH2HSD17B10PKM | |
| SCHEMBL2591427 | 0.74 | EED (0.46) | KDM4EALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL2591769 | 0.74 | KDM4E (0.36) | KDM4EEZH2PKMEEDRBBP4 | |
| SCHEMBL9887625 | 0.72 | EZH2 (0.45) | EZH2EEDRBBP4SUZ12AEBP2 | |
| Trifluoroacetic Acid SCHEMBL1695283 | 0.71 | EZH2 (0.37) | KDM4ELMNAEZH2PKMMAPK1 | |
| SCHEMBL17970561 | 0.70 | EZH2 (0.40) | KMT2AEZH2EEDRBBP4SUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10478426-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2018-07-26 | — | — | US | disclosed |
| US-9956210-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20170095461-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2017-04-06 | — | — | US | disclosed |
| US-9562041-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| EP-2646020-B1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2016-09-21 | — | — | EP | disclosed |
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9114141-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150141436-A1 | INDOLES | KIDS2, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150126522-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-05-07 | — | — | US | disclosed |
| US-8975291-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140256739-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2014-09-11 | — | — | US | disclosed |
| US-8765792-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130345200-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2013-12-26 | — | — | US | disclosed |
| US-20130245016-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-09-19 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245016-A1 | INDOLES | IDO1, IDO2, INMT | KDM4E 1312/4885ALDH1A1 38/4885MEN1 783/4885 |
| US-20150141436-A1 | INDOLES | IDO1, IDO2, INMT | KDM4E 1312/4885ALDH1A1 38/4885MEN1 783/4885 |
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, EZH1, BMI1 | KDM4E 43/4885ALDH1A1 1092/4885MEN1 673/4885 |
| US-20140256739-A1 | METHOD OF TREATMENT | EZH1, EZH2, SUV39H2 | KDM4E 130/4885ALDH1A1 1584/4885MEN1 3219/4885 |
| US-20170095461-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, EZH1, BMI1 | KDM4E 43/4885ALDH1A1 1092/4885MEN1 673/4885 |
| US-10478426-B2 | Enhancer of Zeste Homolog 2 inhibitors | EZH2, EZH1, BMI1 | KDM4E 43/4885ALDH1A1 1092/4885MEN1 673/4885 |
| US-20130345200-A1 | INDOLES | IDO1, IDO2, INMT | KDM4E 1312/4885ALDH1A1 38/4885MEN1 783/4885 |
| US-20150126522-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, EZH1, BMI1 | KDM4E 42/4885ALDH1A1 1379/4885MEN1 658/4885 |
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | KDM4E 1253/4885ALDH1A1 45/4885MEN1 795/4885 |
| US-20160296518-A1 | INDOLES | IDO1, IDO2, INMT | KDM4E 1312/4885ALDH1A1 38/4885MEN1 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.